Please wait while we load the requested 10-Q report or click the link below:
For Investors: Rebecca Peterson, (781) 609-6378
For Media: Jennifer Snyder, (781) 609-6166
|||Announcement of financially transformative merger agreement with Elan Drug Technologies (EDT) that is expected to close in September 2011.|
|||Revenues of $61.9 million, driven by strong manufacturing and royalty revenues from RISPERDAL® CONSTA®. Worldwide sales of RISPERDAL CONSTA by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen-Cilag were approximately $404 million.|
|||GAAP net loss of $13.2 million and pro forma net income of $1.9 million.|
|||Strong financial position, with cash and total investments of $285.4 million as of June 30, 2011.|
|||Partner Amylin Pharmaceuticals, Inc. submitted its reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON; submission will likely be categorized as a Class 2 resubmission requiring up to six months for review.|
|||BYDUREON received marketing authorization in the EU for the treatment of type 2 diabetes and was launched in the U.K., triggering a $7.0 million milestone payment to Alkermes to be recorded in full in the second quarter of fiscal 2012.|
|||Phase 2b study for ALKS 37 for the treatment of opioid-induced constipation initiated.|
Page 1 of 7
The following information was filed by Alkermes Inc on Monday, August 1, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Alkermes Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alkermes Inc.